| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c808ea03599be96bf5a15d638f16aee |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2509-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6901
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0668
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0644 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2020-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38fb5d01cd579997e6c25f309e6f94d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8be2e3279fc4c1e6ee2426a49e9a304e |
| publicationDate |
2020-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-112089847-A |
| titleOfInvention |
A kind of stem cell drug fused with PNV targeting ischemic myocardial blood vessels and preparation method |
| abstract |
The invention discloses a stem cell drug fused with PNV to target ischemic myocardial blood vessels, comprising cardiovascular precursor stem cells, and platelet membrane nanovesicles PNV are fused on the surface of the cardiovascular precursor stem cells. The invention utilizes the biological characteristics of human platelet membrane glycoprotein receptors that naturally target ischemic myocardium and atherosclerotic ischemic blood vessels to prepare platelet membrane nanovesicles PNV, and use PNV to coat cardiovascular precursor stem cells , made into stem cell drugs. PNV not only retains the glycoprotein receptors on the platelet membrane, but can sense a variety of danger signal molecules, and PNV does not have a mechanism to trigger activation of coagulation. It is a natural and safe targeting and navigation substance that can carry vascular precursor stem cells to target Homing to ischemic myocardial blood vessels, to achieve the purpose of precise repair of damaged myocardial blood vessels. The present invention further adopts Flk-1+ cells and arterial adventitial pericytes (APC) two kinds of vascular precursor cells and cooperates with WJMSCs, which can directly differentiate into blood vessels with blood perfusion function. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113332312-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113332312-A |
| priorityDate |
2020-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |